Literature DB >> 24232867

Lack of expression of TUBB3 characterizes both BCL2-positive and BCL2-negative follicular lymphoma.

Alberto Zamò1, Francesco Erdini1, Giovanni Malerba2, Marco Chilosi1.   

Abstract

Follicular lymphoma is characterized by aberrant BCL2 expression, a feature that is exploited for diagnostic purposes. However, a certain percentage of follicular lymphomas might be BCL2-negative by immunohistochemistry, increasing the difficulties in differentiating them from follicular hyperplasia. The expression of TUBB3 has been recently reported as negative in a small series of follicular lymphomas. We have therefore tested a larger series, including 61 BCL2-positive and 25 BCL2-negative cases, and compared them with 61 reactive lymphoid tissues. First, a subjective score of TUBB3 staining was applied, showing that it was consistently positive in reactive germinal centers, while most follicular lymphomas were negative; in fact, only 10/61 (16%) BCL2-positive and 1/25 (4%) BCL2-negative cases showed a positive staining for TUBB3, while 58/61 (95%) of tissues with follicular hyperplasia were positive. The application of a standardized scoring system to a large number of follicles, based on virtual slides, demonstrated that reactive lymphoid tissues had a significantly higher number of TUBB3-positive follicles both compared with BCL2-positive cases and to BCL2-negative cases. Our data support the use of TUBB3 staining in differentiating follicular lymphoma, including BCL2-negative cases, from follicular hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24232867     DOI: 10.1038/modpathol.2013.182

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  1 in total

1.  Protocadherin γ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth.

Authors:  Xueyan Zhang; Katsuyoshi Takata; Wei Cui; Tomoko Miyata-Takata; Yasuharu Sato; Mai Noujima-Harada; Tadashi Yoshino
Journal:  Mol Med Rep       Date:  2016-10-05       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.